Richard Peters
CIK: 0001697628
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Jun 16, 2026APRE
Aprea Therapeutics, Inc.
Award(A)Direct3.1K shares- - Mar 31, 2026APRE
Aprea Therapeutics, Inc.
Purchase(P)DirectPre-Funded Warrant
123.9K shares at avg. $0.81- - Mar 31, 2026APRE
Aprea Therapeutics, Inc.
Purchase(P)DirectCommon Warrant
123.9K shares- - Jun 30, 2025KANT
KINETA, INC./DE
Disposition(D)Direct101.9K shares- - Jun 25, 2025KANT
KINETA, INC./DE
Award(A)Direct6K shares- - Jun 23, 2025KANT
KINETA, INC./DE
Tax Payment(F)Direct4.7K shares at avg. $0.26$1K - Jun 23, 2025KANT
KINETA, INC./DE
Exercise(M)Direct12.5K shares at avg. $0.61$8K - Jun 5, 2025APRE
Aprea Therapeutics, Inc.
Award(A)Direct1K shares- - Sep 4, 2024KA
KINETA, INC./DE
Award(A)DirectStock Option (Right to Buy)
12.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 16, 2026 |  APRE Aprea Therapeutics, Inc. | Award(A) | 3,135 | - | $0 | Direct |
| Mar 31, 2026 | APRE Aprea Therapeutics, Inc. | Purchase(P) Pre-Funded Warrant | 123,915 | $0.81 | - | Direct |
| Mar 31, 2026 | APRE Aprea Therapeutics, Inc. | Purchase(P) Common Warrant | 123,915 | - | - | Direct |
| Jun 30, 2025 |  KANT KINETA, INC./DE | Disposition(D) | 101,891 | - | - | Direct |
| Jun 25, 2025 | KANT KINETA, INC./DE | Award(A) | 6,000 | - | - | Direct |
| Jun 23, 2025 | KANT KINETA, INC./DE | Tax Payment(F) | 4,706 | $0.26 | $1,224 | Direct |
| Jun 23, 2025 | KANT KINETA, INC./DE | Exercise(M) | 12,500 | $0.61 | $7,638 | Direct |
| Jun 5, 2025 | APRE Aprea Therapeutics, Inc. | Award(A) | 1,045 | - | - | Direct |
| Sep 4, 2024 |  KA KINETA, INC./DE | Award(A) Stock Option (Right to Buy) | 12,500 | - | - | Direct |
1-9 of 9 transactions
About Peters Richard
Peters Richard (SEC CIK 0001697628) files insider reports with the SEC as Director of Aprea Therapeutics, Inc. (APRE) and Director of KINETA, INC./DE (KA).
Signal8 holds 6 ownership filings by Peters Richard, all Form 4s, filed between Sep 5, 2024 and Jun 17, 2026. Those filings report 9 transactions, from Sep 4, 2024 to Jun 16, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Peters Richard's filings is in DOYLESTOWN, PA.
Recent filings by Peters Richard
- Jun 16, 2026: Grant or award of APRE shares (Form 4, code A).
- Mar 31, 2026: Open-market purchases of APRE derivative securities (2 lines, Form 4, code P).
- Jun 30, 2025: Disposition to issuer transaction of KANT shares (Form 4, code D).
- Jun 25, 2025: Grant or award of KANT shares (Form 4, code A).
- Jun 23, 2025: Tax withholding of KANT shares (Form 4, code F).
Other insiders filing for Aprea Therapeutics, Inc. (APRE)
- Grissinger Michael, Director
- Gruia Gabriela, Director
- HENNEMAN JOHN B III, Director
- BIZZARI JEAN-PIERRE, Director
- Duey Marc, Director
- Pamukcu Rifat, Director